What's New?

  • Email
  • Help

March 2017

Filter by:
Date Content
01/03/2017Human medicines European public assessment report (EPAR): Ibandronic acid Accord,

ibandronic acid

Revision: 6, Authorised
01/03/2017Eligible patients and consumers organisations (updated)
01/03/2017Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 February 2017, adopted
01/03/2017Report: List of products granted eligibility to PRIME (updated)
01/03/2017PRIME: priority medicines (updated)
01/03/2017Human medicines European public assessment report (EPAR): Lantus,

insulin glargine

Revision: 30, Authorised
01/03/2017Veterinary medicine European public assessment report (EPAR): Porcilis PCV M Hyo,

porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)

Revision: 2, Authorised
01/03/2017Human medicines European public assessment report (EPAR): Sifrol,

pramipexole

Revision: 28, Authorised
01/03/2017Human medicines European public assessment report (EPAR): Docetaxel Kabi,

docetaxel

Revision: 7, Authorised
01/03/2017Veterinary medicine European public assessment report (EPAR): Profender,

emodepside / praziquantel

Revision: 13, Authorised
01/03/2017Information day on medication errors, European Medicines Agency, London, UK, From: 20-Oct-2016, To: 20-Oct-2016 (updated)
01/03/2017Human medicines European public assessment report (EPAR): Cervarix,

human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)

Revision: 27, Authorised
01/03/2017Human medicines European public assessment report (EPAR): Dacogen,

decitabine

Revision: 8, Authorised
01/03/2017Human medicines European public assessment report (EPAR): Voriconazole Hikma ,

voriconazole

Revision: 3, Authorised
01/03/2017Human medicines European public assessment report (EPAR): Xagrid,

anagrelide

Revision: 29, Authorised